Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.
Rydex Biotechnology Inv RYOIX
- NAV / 1-Day Return 74.86 / +1.49 %
- Total Assets 110.0 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.390%
- Distribution Fee Level Above Average
- Share Class Type No Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield —
- Turnover 61%
USD | NAV as of Mar 27, 2024 | 1-Day Return as of Mar 27, 2024, 10:19 PM GMT+0
Morningstar’s Analysis RYOIX
Will RYOIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings —
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
AbbVie Inc | 8.54 | 9.5 Mil | Healthcare |
Amgen Inc | 6.64 | 7.4 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 4.41 | 4.9 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.36 | 4.8 Mil | Healthcare |
Gilead Sciences Inc | 4.00 | 4.4 Mil | Healthcare |
Moderna Inc | 3.16 | 3.5 Mil | Healthcare |
Biogen Inc | 2.89 | 3.2 Mil | Healthcare |
Corteva Inc | 2.71 | 3.0 Mil | Basic Materials |
AstraZeneca PLC ADR | 2.68 | 3.0 Mil | Healthcare |
Illumina Inc | 2.48 | 2.8 Mil | Healthcare |